JP Morgan Initiates Coverage On Amphastar Pharma with Overweight Rating, Announces Price Target of $60
Portfolio Pulse from Benzinga Newsdesk
JP Morgan analyst Ekaterina Knyazkova initiates coverage on Amphastar Pharma (NASDAQ:AMPH) with an Overweight rating and a price target of $60.
March 05, 2024 | 11:21 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
JP Morgan initiated coverage on Amphastar Pharma with an Overweight rating and set a price target of $60.
The initiation of coverage by a major financial institution like JP Morgan, especially with an Overweight rating and a significant price target of $60, is likely to generate positive sentiment among investors. This could lead to increased buying activity in the short term, pushing the stock price up.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100